Mid-March, Desirée and I were invited to join this year’s ACC convention which took place in New Orleans. The goal was to showcase our life with the HeartMate3 VAD system and advocate for patients like me, to health professionals and medical organisations. It was also an opportunity to meet some of the folks leading the advancement of heart health, developing novel technologies, and therapies.
We took some time to discover NOLA, some of its food, and the music. We even went to an NBA game and also caught up with a long-time friend whom I had not seen for almost 10 years while in South Africa.
Going to the convention was a great experience, we’ve learned so much and met many inspirational patients and great professionals. The conversations were all so meaningful and we appreciated the interest many have shown in our story.
Remarkably, the two-year survival data of the Heartmate3 were released, at the convention - showing a rate that is comparable to that of heart transplantation (Abbott)(NEJM). This news was a pleasant surprise and I believe this may be encouraging for the improvement of mechanical circulatory systems.
Special moment at the ACC.19 when we reunited with my doctors, same place, same time.
The special moment for us at the convention came early on the first day when Desirée and I were reunited with three healthcare providers who greatly impacted my life.
Dr. Dieye Ousmane treated my dilated cardiomyopathy in Dakar, Senegal. When I flew to UC Davis for the fellowship and my heart failure was triggered, Dr. Xu ZI-Jian and his team at Sutter Medical Health Center in Sacramento stabilised me and knew I needed an LVAD while I waited for a heart transplant. Because we had family in Boston, Dr. Xu referred me to the Brigham & Women’s, which is where we moved as well. I was implanted with the Heartmate3 LVAD there. Dr. Givertz Michael is part of the team that implanted me and follow my care.
Thank you for reading.
Please check back often for updates. Updates may be infrequent, but continue to stop by for anything new!
Sign up for the newsletter.